Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Rating of Moderate Buy from Analysts

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) have received a consensus rating of “Moderate Buy” from the fourteen brokerages that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, seven have issued a buy recommendation and one […]

Related Keywords

United States ,America ,Raymond James ,B Lynne Parshall ,William Blair ,Clearbridge Investments ,Vanguard Group Inc ,Nasdaq ,Ionis Pharmaceuticals Stock Down ,Ionis Pharmaceuticals Company Profile ,Insider Activity At Ionis Pharmaceuticals ,T Rowe Price Investment Management Inc ,Morgan Stanley ,News Ratings For Ionis Pharmaceuticals Daily ,Ionis Pharmaceuticals Inc ,Hedge Funds Weigh In On Ionis Pharmaceuticals ,Analyst Recommendations For Ionis Pharmaceuticals ,Ionis Pharmaceuticals ,Get Free Report ,Pharmaceuticals Stock Down ,Directorb Lynne Parshall ,Rowe Price Investment Management ,Camber Capital Management ,Capital Management ,Get Free ,Ionis Pharmaceuticals Daily ,Nasdaq Ions ,Lions ,Medical ,46433010 ,Ratings ,Consensus ,